SCHEMBL2433967

SCHEMBL2433967

CCOC(=O)CC(=O)Nc1cc(-c2cc(C)c3ccccc3n2)n[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.48
PKM P14618 1/20 0.47
MAPT P10636 3/20 0.47
KMT2A Q03164 2/20 0.47
TOP2A P11388 2/20 0.43
POLB P06746 3/20 0.43
KDM4E B2RXH2 3/20 0.43
GLA P06280 1/20 0.43
ELANE P08246 3/20 0.42
TP53 P04637 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
F2 P00734 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
PDE5A O76074 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2440479 0.81 MAPK1 (0.48) MAPK1PKMMAPTKMT2AKDM4E
SCHEMBL2436255 0.81 MAPK1 (0.50) MAPK1PKMMAPTKMT2ATOP2A
SCHEMBL2440253 0.79 MAPK1 (0.48) MAPK1PKMMAPTKMT2APOLB
SCHEMBL2440866 0.77 PKM (0.45) MAPK1PKMMAPTKMT2AKDM4E
SCHEMBL2439066 0.77 PKM (0.45) MAPK1PKMMAPTKMT2AKDM4E
SCHEMBL2436315 0.77 MAPK1 (0.46) MAPK1PKMMAPTKMT2APOLB
SCHEMBL14120046 0.77 PKM (0.51) MAPK1PKMMAPTKMT2AF2
SCHEMBL2441561 0.75 PKM (0.47) MAPK1PKMMAPTKMT2AKDM4E
SCHEMBL2435765 0.72 PKM (0.46) MAPK1PKMMAPTKMT2AKDM4E
SCHEMBL2436439 0.72 PKM (0.46) MAPK1PKMMAPTKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2539342-B1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2015-04-15 EP disclosed
US-8969376-B2 Pyrazolopyrimidine compounds and their use as PDE10 inhibitors MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-03-03 US disclosed
EP-2539342-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS Mitsubishi Tanabe Pharma Corporation (JP) 2013-01-02 EP disclosed
US-20120309754-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-12-06 US disclosed
WO-2011105628-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309754-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS PDE3B, PDE3A, PDE5A MAPK1 286/4885PKM 296/4885MAPT 4404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.